Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.72 |
| ▸ | MMP3 | P08254 | 18/20 | 0.72 |
| ▸ | MMP13 | P45452 | 18/20 | 0.72 |
| ▸ | MMP2 | P08253 | 17/20 | 0.72 |
| ▸ | MMP8 | P22894 | 17/20 | 0.72 |
| ▸ | MMP9 | P14780 | 4/20 | 0.72 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.72 |
| ▸ | MMP7 | P09237 | 1/20 | 0.72 |
| ▸ | MMP14 | P50281 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674756 | 1.00 | MMP1 (0.72) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7665791 | 1.00 | MMP1 (0.72) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7093126 | 1.00 | MMP1 (0.72) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7874423 | 0.89 | MMP1 (0.79) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL10118168 | 0.89 | MMP1 (0.75) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7874425 | 0.89 | MMP1 (0.79) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7091833 | 0.86 | MMP1 (0.80) | MMP1MMP3MMP13MMP2MMP8 | |
| SCHEMBL7088211 | 0.86 | MMP1 (0.80) | MMP1MMP3MMP13MMP2MMP8 | |
| Cipemastat SCHEMBL10321896 | 0.83 | MMP1 (1.00) | MMP1MMP3MMP13MMP2MMP8 | |
| Cipemastat SCHEMBL7297043 | 0.83 | MMP1 (1.00) | MMP1MMP3MMP13MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0816341-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | claimed |
| EP-1052249-B1 | Process for the preparation of hydroxamic acids | HOFFMANN LA ROCHE (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-6452010-B1 | HYDROXAMIC ACID DERIVATIVES OF CERTAIN CARBOXYLIC ACIDS HAVE BEEN RECOGNIZED AS INHIBITORS OF MATRIX METALLOPROTEINASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-6316633-B1 | CARTILAGE PROTECTIVE AGENTS AND USEFUL IN THE THERAPY AND PROPHYLAXIS OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-11-13 | — | — | US | disclosed |
| US-6197995-B1 | INTERMEDIATES FOR CARTILAGE PROTECTIVE AGENTS USEFUL IN TREATMENT AND PREVENTION OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-03-06 | — | — | US | disclosed |
| US-6172238-B1 | Process for manufacturing 1-[3-cyclopentyl-2(R)-[1(R)-hydroxycarbamoyl)-2-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)ethyl]propionyl]piperidine | HOFFMANN-LA ROCHE INC. | 2001-01-09 | — | — | US | disclosed |
| EP-1052249-A1 | Process for the preparation of hydroxamic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| US-6031103-A | Process for manufacturing 1-[3-cyclopentyl -2(R)-[1(R)-hydroxycarbamoyl)-2-(3, 4, 4-trimethyl -2, 5-D ioxo-1-imidazolidinyl) ethyl] propionyl] piperidine | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0911324-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-28 | — | — | EP | disclosed |
| EP-0816341-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | disclosed |